20245-39-0

Usage

Uses

Used in Pharmaceutical Industry:
1,3,7-Trihydroxy-2-prenylxanthone is used as a therapeutic agent for its antioxidant, anti-inflammatory, anticancer, and neuroprotective properties, making it a candidate for the development of new treatments for various health conditions.
Used in Cosmetic and Skincare Industry:
1,3,7-Trihydroxy-2-prenylxanthone is used as a natural dye and an ingredient in cosmetic and skincare products for its pigment and antioxidant properties, contributing to the formulation of products that promote skin health and appearance.
Used in Natural Dye Industry:
1,3,7-Trihydroxy-2-prenylxanthone is used as a natural dye due to its pigment properties, offering an eco-friendly alternative to synthetic dyes in various applications.

Upstream product

• 529-49-7 gentitein 
• 870-63-3 prenyl bromide 
• 108-73-6 3,5-dihydroxyphenol 
• 490-79-9 2,5-dihydroxybenzoic acid. 
• 358-72-5 dimethylallyl diphosphate 

Relevant academic research and scientific papers

Regiospecific Prenylation of Hydroxyxanthones by a Plant Flavonoid Prenyltransferase

C-Prenylated xanthones are pharmacologically attractive specialized metabolites that are distributed in plants and microorganisms. The prenylation of xanthones often contributes to the structural diversity and biological activities of these compounds. However, efficient regiospecific prenylation of xanthones is still challenging. In this study, the regiospecific prenylation of a number of structurally different hydroxyxanthones (3-10) by MaIDT, a plant flavonoid prenyltransferase with substrate flexibility from Morus alba, is demonstrated. Among the enzymatic products, 2-dimethylallyl-1,3,7-trihydroxyxanthone (3a) effectively attenuated glutamate-induced injury in SK-N-SH neuroblastoma cells. These results suggest a potential approach for the synthesis of bioactive prenylated xanthones by a substrate-relaxed flavonoid prenyltransferase.

Synthesis, SAR and biological evaluation of natural and non-natural hydroxylated and prenylated xanthones as antitumor agents

In order to explore the detailed structure-activity relationship (SAR) around xanthone scaffold bearing hydroxyl and prenyl moieties, twenty-nine natural and non-natural hydroxylated and prenylated xanthones have been synthesized and evaluated for their in vitro anti-proliferative activities against five human cancer cell lines, including HepG2 (hepatocelluar carcinoma), HCT-116 (colon carcinoma), A549 (lung carcinoma), BGC823 (gastric carcinoma) and MDAMB- 231 (breast carcinoma). The SAR analysis revealed that the anti-proliferative activity of the xanthones is substantially influenced by the position and number of attached hydroxyl and prenyl groups, and the presence of hydroxyl group ortho to the carbonyl function of xanthone scaffold contributes significantly to their cytotoxicity. The new prenylated xanthone 20 with a relatively simple structure, namely 1,3,8-trihydroxy-2-prenylxanthone, was found to exhibit potent antitumor activities comparable to mangostin against all the five cancer cell lines. Further mechanistic studies suggested that compound 20 induces apoptosis and causes cell cycle arrest at S phase in HepG2 cells. These results have highlighted compound 20 as a new potential lead candidate for future development of novel potent broad-spectrum antitumor agents.